Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women

Recruiting now · Phase 4

Conditions studied: Vagina Atrophy

In brief

This study investigates whether vaginal estrogen treatment has an effect on hemostatic parameters in postmenopausal women. Blood samples are collected before and after 3 months treatment to assess changes in hemostasis.

Key facts

Study ID

NCT07160504

Run by

University of Aarhus

People needed

90

Starts

2025-03-21

Expected to finish

2026-12-31

Last updated by the study team

2025-09-08

Who can join

Age: 50 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women aged ≥ 50
• Symptomatic vaginal atrophy
• Indication for standard treatment with vaginal estrogen tablets 10 µg at least three times a week
• Study population 1: without a history of venous thromboembolic event
• Study population 2: with a history of venous thromboembolic event

You may not qualify if…

• Unable to give written informed consent
• Does not speak Danish
• Current cancer treatment
• Current treatment with blood thinning medication (except plateletinhibitor)
• Current treatment with local or systematic estrogen
• Systemic inflammatory disease, liver disease or kidney disease

Where it is running

• Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark — Aarhus N, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.